An Intuitive, Non-intrusive, Approach to Reduce Patient Harm From Inappropriate Dosing of High-risk Drugs in Older Adult Patients Across an Urban Safety Net Hospital System
NCT ID: NCT05218343
Last Updated: 2023-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8640 participants
INTERVENTIONAL
2022-02-16
2022-08-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Analyses ongoing, expected to finalize spring 2023
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Electronic Prescribing and Electronic Transmission of Discharge Medication Lists
NCT00603070
Improving Safety By Computerizing Outpatient Prescribing
NCT00235027
Impact of Vendor Systems on Ambulatory Medication Safety
NCT00773500
Evaluations of CDS Systems
NCT06330740
Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges: Pilot Phase
NCT03791580
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
Other inputs used for trial design were: baseline rate of prescriptions meeting the geriatric standard (sources: local data, Geriatrics At Your Fingertips), within-period intraclass correlation coefficient (ICC, correlation between two randomly chosen observations in the same cluster), cluster autocorrelation (ratio of between-period ICC to within-period ICC), and coefficient of variation of cluster sizes (required when unequal sample size per cluster is expected). The aim is for ≥80% power to detect a ≥50% increase in prescriptions meeting the geriatric standard; this is based on previous studies and on the researchers' preliminary data on Trazodone.
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
No change in default dose or frequency selected for the eight targeted drugs
No interventions assigned to this group
Intervention
The first option a prescriber sees when prescribing any of eight high-risk drugs for elderly hospitalized patients will be modified; the first frequency option a prescriber sees will be modified as well. Providers retain the ability to prescribe any dose or frequency.
EHR-based "nudge" interventions
Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EHR-based "nudge" interventions
Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 65-years old or older
* receive one of the targeted medications
Exclusion Criteria
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York City Health and Hospitals Corporation
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jashvant Poeran
Associate Professor Depts. of Population Health Science & Policy / Orthopedics / Medicine Director, Center for Clinical and Outcomes Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jashvant Poeran, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NYC Health+Hospitals
New York, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GCO-21-0383
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.